Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2013 Results
Date:11/7/2013

WASHINGTON, Nov. 7, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2013.

Key Highlights:

  • On July 29, 2013 Vanda announced that the U.S. Food and Drug Administration (FDA) accepted the filing of and granted priority review classification to Vanda's New Drug Application (NDA) for tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind.
  • The FDA has scheduled a Peripheral and Central Nervous System Drugs Advisory Committee Meeting on November 14, 2013, for the review of Vanda's NDA for tasimelteon, proposed trade name HETLIOZ™, for the treatment of Non-24.
  • The FDA determined the action target date under the Prescription Drug User Fee Act (PDUFA-V) for tasimelteon to be January 31, 2014. 
  • On August 7, 2013 Vanda completed the public offering of 4.68 million shares of common stock resulting in net proceeds of $48.6 million. 
  • Vanda recorded third quarter 2013 revenue of $8.7 million including royalties of $2.0 million.  Fanapt® prescriptions, as reported by IMS, were approximately 43,600 for the third quarter of 2013.  This represents a 13% increase over third quarter 2012 prescriptions and a 5% increase over second quarter 2013 prescriptions.
  • THIRD QUARTER 2013 REPORTED RESULTSTotal revenues for the third quarter of 2013 were $8.7 million, compared to $8.3 million for the same period in 2012.  Third quarter 2013 revenues included $2.0 million in Fanapt® royalties received from Novartis as compared to royalties of $1.5 million for the third quarter of 2012.

    Total operating expenses for the third quarter of 2013 were $14.1 million, compared to $13.7 million for the third quarter of 2012.  Third quarter 2013 research and development expenses of $8.0 million includes $3.5 million in milestones associated with the FDA acceptance of the tasimelteon filing.  The primary driver of the lower research and development expenses in the third quarter of 2013 as compared to $10.2 million in the third quarter of 2012 was the completion of the tasimelteon Non-24 and Major Depressive Disorder efficacy studies.  General and administrative expenses of $5.7 million for the third quarter of 2013 were $2.6 million higher than the third quarter of 2012 and reflect the increased commercial activity in preparation for a potential tasimelteon commercial launch in the United States.

    Vanda recorded a net loss of $5.4 million for the third quarter of 2013, compared to a net loss of $5.3 million for the same period in 2012.  Diluted net loss per share for the third quarter of 2013 was $0.17, compared to a diluted net loss per share of $0.19 for the third quarter of 2012.

    Cash, cash equivalents and marketable securities (Cash) increased by $38.5 million to $142.2 million as of September 30, 2013, primarily as a result of the sale of common stock in Vanda's public offering in August 2013.Year to Date September 30, 2013 Key Financial Figures1Nine Months EndedSeptember 30September 30($ in thousands, except per share amounts)20132012  Change ($)Change (%)Total revenues

    $
    25,096$
    24,807$
    2891%Research & development  expenses

    21,96834,829(12,861)(37%)General & administrative expenses

    14,74310,6574,08638%Non-cash stock-based compensation2

    3,3213,1711505%Net loss

    (12,632)(21,295)8,66341%Diluted net loss per share

    $
    (0.43)$
    (0.75)$
    .3243% Third Quarter 2013 Key Financial Figures1Three Months EndedSeptember 30June 30($ in thousands, except per share amounts)20132013  Change ($)Change (%)Total revenues

    $
    8,709$
    8,319$
    3905%Research & development  expenses

    8,0265,9822,04434%General & administrative expenses

    5,7115,07463713%Non-cash stock-based compensation2

    1,53983070985%Net loss

    (5,380)(3,079)(2,301)(75%)Diluted net loss per share

    $
    (0.17)$
    (0.11)$
    (0.06)(55%)Select Cash Flow Data1 Nine Months EndedSeptember 30September 30($ in thousands)20132012Net cash provided by (used in)Operating activities

    $ (27,439)$ (31,068)Investing activities

    31,42147,660Financing activities

    49,418- Select Balance Sheet Data1 September 30June 30September 30($ in thousands)201320132012Total cash and marketable securities

    $
    42,172$
    3,633$
    34,404(1) Unaudited(2) Non-cash stock-based compensation is allocated to both Research & development and General & administrative expenses  

    OPERATIONAL HIGHLIGHTSOn July 29, 2013, Vanda announced that the FDA accepted the filing of and granted a priority review classification to Vanda's NDA for tasimelteon, a circadian regulator for the treatment of Non-24 in the totally blind.  Currently, there is no approved treatment for Non-24 and tasimelteon has the potential to address this unmet medical need.  The FDA has scheduled a Peripheral and Central Nervous System Drugs Advisory Committee Meeting on November 14, 2013, for the review of Vanda's NDA for tasimelteon, proposed trade name HETLIOZ™, for the treatment of Non-24.  The FDA determined the action target date under the Prescription Drug User Fee Act (PDUFA-V) for tasimelteon to be January 31, 2014. 

    Vanda recorded third quarter 2013 revenue of $8.7 million including $6.7 million in licensing revenue related to the amortization of the upfront payment received from Novartis for U.S. and Canadian commercial rights to Fanapt® and Fanapt® royalties of $2.0 million.  Fanapt® prescriptions, as reported by IMS, were approximately 43,600 for the third quarter of 2013.  This represents a 13% increase over third quarter 2012 prescriptions and a 5% increase versus second quarter 2013 prescriptions.2013 FINANCIAL GUIDANCE2013 expenses are expected to reflect lower research and development spending as compared to 2012 and an increase in commercial spending.  Reflecting the recent public offering and year to date expenditures, Vanda now expects that it will end the year with between $130.0 and $135.0 million in Cash.  Total 2013 operating expenses are expected to be between $50.0 and $55.0 million and decrease in Cash, excluding the impact of the recent public offering, is expected to be between $35.0 and $40.0 million.

    CONFERENCE CALLVanda has scheduled a conference call for today, Thursday, November 7, 2013, at 10:00 AM ET.  During the call, Vanda's management will discuss the third quarter 2013 financial results and other corporate activities.  Investors can call 1-888-895-5271 (domestic) and 1-847-619-6547 (international) and use passcode 35919679.  A replay of the call will be available beginning Thursday, November 7, 2013 at 12:00 PM ET and will be accessible until Thursday, November 14, 2013, at 5:00 PM ET.  The replay call-in number is 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers.  The access number is 35919679.

    The conference call will be broadcast simultaneously on Vanda's website, www.vandapharma.com.  Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations.  The call will also be archived on Vanda's website for a period of 30 days.

    ABOUT VANDA PHARMACEUTICALS INC.:Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit www.vandapharma.com.

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSVarious statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "goal," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.  Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: Vanda's failure to obtain, or any delay in obtaining, regulatory approval for tasimelteon for the treatment of Non-24-Hour Disorder or to comply with ongoing regulatory requirements; the costs and effects of current or potential litigation and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2012 which is on file with the SEC and available on the SEC's website at www.sec.gov and Vanda's quarterly report on Form 10-Q for the quarter ended September 30, 2013 to be filed with the SEC.  In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results.  There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda.  Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

    All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein.  Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf.  The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. VANDA PHARMACEUTICALS INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)Three Months EndedNine Months EndedSeptember 30September 30September 30September 30($ in thousands, except per share amounts)

    2013201220132012Revenues:Licensing agreement

    $

    6,753$

    6,753$

    20,037$

    20,037Royalty revenue1,9561,5355,0594,770Total revenues8,7098,28825,09624,807Operating expenses:Research and development8,02610,15921,96834,829General and administrative5,7113,14714,74310,657Intangible asset amortization3773771,1181,118Total operating expenses14,11413,68337,82946,604Loss from operations(5,405)(5,395)(12,733)(21,797)Other income2569101502Loss before tax benefit(5,380)(5,326)(12,632)(21,295)Tax benefit----Net loss

    $

    (5,380)$

    (5,326)$

    (12,632)$

    (21,295)Net loss per share:Basic

    $

    (0.17)$

    (0.19)$

    (0.43)$

    (0.75)Diluted

    $

    (0.17)$

    (0.19)$

    (0.43)$

    (0.75)Shares used in calculations of net lossper share:Basic 31,332,99328,226,74329,363,16228,226,743Diluted31,332,99328,226,74329,363,16228,226,743 VANDA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)($ in thousands)September 30, 2013December 31, 2012ASSETSCurrent assets:Cash and cash equivalents$

    142,172$

    88,772Marketable securities-31,631Accounts receivable1,9561,168Prepaid expenses and other current assets

    2,4123,967Restricted cash, current530430Total current assets147,070125,968Property and equipment, net2,1062,348Intangible asset, net5,4146,532Restricted cash, non-current500600Total assets$

    155,090$

    135,448LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$

    369$

    287Accrued liabilities4,5325,187Deferred rent, current215-Deferred revenues, current26,78926,789Total current liabilities31,90532,263Deferred rent, non-current2,9453,005Deferred revenues, non-current70,23890,275Total liabilities105,088125,543Stockholders' equity:Common stock3328Additional paid-in capital353,708300,974Accumulated other comprehensive income-10Accumulated deficit(303,739)(291,107)Total stockholders' equity50,0029,905Total liabilities and stockholders' equity

    $

    155,090$

    135,448INVESTOR CONTACT:
    Chad Rubin
    Vice President
    The Trout Group
    (646) 378-2947
    crubin@troutgroup.com


    '/>"/>
    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Vanda Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 7, 2013
    2. Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock
    3. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
    4. Vanda Pharmaceuticals Reports Second Quarter 2013 Results
    5. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
    6. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
    7. Vanda Pharmaceuticals, Inc. Sued by Investor
    8. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
    9. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
    10. Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
    11. Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
    (Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
    (Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
    Breaking Medicine Technology:
    (Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
    (Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
    (Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
    (Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
    (Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
    Breaking Medicine News(10 mins):